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Abstract 
Prospective population studies in the primary prevention setting have shown that reduced plasma levels of 
HDL cholesterol are associated with an increased risk of coronary disease and myocardial infarction.  
Experimental and translational studies have further revealed several potential anti-atherogenic effects of 
HDL, including protective effects on endothelial cell functions.  HDL has been suggested to protect 
endothelial cell functions by prevention of oxidation of LDL and its adverse endothelial effects.  Moreover, 
HDL from healthy subjects can directly stimulate endothelial cell production of nitric oxide, anti-
inflammatory, anti-apoptotic and anti-thrombotic effects as well as endothelial repair processes.   
However, several recent clinical trials using HDL cholesterol raising agents, such as torcetrapib, dalcetrapib 
and niacin, did not demonstrate a significant reduction of cardiovascular events in patients with coronary 
disease.  Of note, growing evidence suggests that the vascular effects of HDL can be highly heterogenous 
and vasoprotective properties of HDL are altered in patients with coronary disease. Characterization of 
underlying mechanisms and understanding of the clinical relevance of this “HDL dysfunction” are currently 
an active field of cardiovascular research.  Notably, in some recent studies no clear association of higher 
HDL cholesterol levels with a reduced risk of cardiovascular events was observed in patients with already 
established coronary disease.  A greater understanding of mechanisms of action of HDL and its altered 
vascular effects is therefore critical within the context of HDL-targeted therapies.  In this review, we will 
address different effects of HDL on endothelial cell functions potentially relevant to atherosclerotic vascular 
disease and explore molecular mechanisms leading to “dysfunctional HDL”.  
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Introduction 
Large prospective studies of cardiovascular risk factors have shown that reduced plasma levels of HDL 
cholesterol are associated with an increased risk of coronary artery disease (CAD) (1-5). In recent years, 
several biological functions of HDL have been identified, whereby HDL may exert anti-atherogenic effects 
(6-8); e.g. HDL from healthy subjects has been shown to directly promote endothelial anti-inflammatory, 
anti-apoptotic and anti-thrombotic effects (7, 9-12) (Figure 1).  Accordingly, interventions to increase HDL-
cholesterol levels and/or HDL-function are being intensely evaluated as a potential therapeutic strategy to 
reduce cardiovascular risk.  However, recent evidence suggests that the endothelial and vascular effects of 
HDL are highly heterogenous and vasoprotective properties of HDL are impaired in patients with diabetes, 
coronary disease or chronic kidney dysfunction (13-16) (Figure 1).  
Various studies have examined the association of genetic variations leading to altered HDL cholesterol 
plasma levels with coronary disease risk (17-19).  These studies suggest that some genetic variations 
associated with higher HDL cholesterol plasma levels may not necessarily be associated with a reduced 
risk of coronary disease or myocardial infarction, although this does not apply for all associations (eg. 
CETP) and for some genes remains inconclusive (20, 21).   
Of note, several recent clinical trials have not been able to demonstrate that therapies that increase HDL 
cholesterol levels reduce cardiovascular risk in patients with coronary disease.  The Investigation of Lipid 
Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial testing the 
impact of the CETP inhibitor torcetrapib on clinical outcome showed an increase in cardiovascular events 
and total mortality, despite elevations in HDL cholesterol, that was, however, at least in part attributed to 
toxic effects of the compound (22). Dalcetrapib, another CETP inhibitor, raised the HDL-cholesterol level 
in patients hospitalized with an acute coronary syndrome, but the trial was terminated before completion 
due to lack of clinical benefit (23). And very recently, the HPS2-THRIVE trial results showed that adding 
extended-release niacin/laropiprant, another HDL-raising agent, to statins did not reduce the risk of 
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cardiovascular events (24).  Taken together, these observations strongly suggest that plasma levels of HDL 
cholesterol alone are not an optimal therapeutic target.   
Importantly, accumulating evidence suggests that the vascular effects of HDL can be highly heterogeneous. 
We and others have observed that HDL loses potential anti-atherosclerotic properties in patients with 
chronic inflammatory disorders, such as the antiphospholipid syndrome (25), systemic lupus erythematosus 
and rheumatoid arthritis (26), scleroderma (27), the metabolic syndrome (28), diabetes (13, 29), and 
coronary disease (15, 16, 30). Notably, in a study of 189 patients with chronic kidney disease on 
hemodialysis an impaired anti-inflammatory capacity of HDL was correlated with a poor clinical outcome 
(31). Furthermore, HDL isolated from subjects with type 1 or type 2 diabetes mellitus or abdominal obesity 
had reduced capacity to reverse the inhibition of aortic ring endothelium-dependent relaxation by oxLDL 
as compared to HDL from healthy control subjects (29, 32, 33). These proinflammatory HDL particles have 
been termed ’dysfunctional’ HDL (Figure 1). The heterogeneity of the vascular effects of HDL may be 
attributed to changes in the HDL-associated proteome and lipids, i.e. post-translational protein 
modifications and changes in the amount and type of proteins and lipids bound to the HDL particle.  In 
particular, high-density lipoprotein is susceptible to oxidation/modification in vitro by a variety of oxidants, 
such as metal ions, peroxyl and hydroxyl radicals, aldehydes, various myeloperoxidase (MPO)-generated 
oxidants, lipoxygenase, phospholipase A2, elastase, non-enzymatic glycation and homocysteinylation (34). 
In the present review, we will address different mechanisms whereby HDL exert effects on endothelial cell 
functions. In particular, the effects of HDL on regulation of endothelial nitric oxide synthase (eNOS) and 
endothelial cell nitric oxide (NO) production, endothelial inflammatory activation, endothelial apoptotic 
regulation, endothelial repair from vascular injury, lipid oxidation and endothelial thrombotic activation 
will be discussed. Importantly, recent insights into molecular mechanisms leading to “HDL dysfunction” 
in different pathophysiological states will be described.  
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Impact of HDL on LDL oxidation and its endothelial effects:  Lessons from experimental studies and 
alterations of HDL from patients with coronary disease or diabetes  
HDL may exert endothelial-protective effects by limiting oxidation of LDL.  Oxidation of LDL has long 
been suggested as a relevant mechanism for atherogenesis (35, 36). LDL is entrapped in the subendothelial 
space where it is subject to oxidative modifications by reactive nitrogen species, myeloperoxidase pathways 
and others (37).  Once formed, oxidized LDL (oxLDL) is a potent inducer of endothelial expression of 
inflammatory molecules (38). OxLDL also promotes the differentiation of monocytes into macrophages 
that take-up oxLDL in a process that converts them into foam cells, hallmark cells of atherosclerotic plaques 
(39).  
Hessler et al. early on reported that HDL protects against LDL-induced cytotoxicity on endothelial cells 
(40). HDL was demonstrated to prevent copper-induced LDL oxidation or LDL oxidation by cultured 
endothelial cells (41-43). HDL is a major carrier of lipid peroxidation products (44, 45) which are thought 
to play a role in the initiation and progression of atherosclerotic vascular disease (46). HDL can directly 
inhibit oxidation of low-density lipoprotein via transfer of oxidation products from LDL to HDL (44). In 
addition, circulating HDL accumulates oxidized phospholipids, such as hydroperoxides, 
lysophosphatidylcholine (lyso-PC) and F2-isoprostanes (44, 45). The transfer of lipid hydroperoxides from 
LDL prevents the initiation of a free radical chain reaction of oxidation (47). Furthermore, some of the 
advanced products of phospholipid oxidation may serve as ligands for scavenger receptor and promote 
uptake of modified lipoproteins by macrophages as well as prothrombotic effects mediated by platelet 
scavenger receptor CD36 (48, 49).  
A study by Navab et al. demonstrated that apoA-I binds to and removes lipid hydroperoxides of LDL in 
vitro and in vivo (47). Treatment of human artery wall cells with apoA-I, but not apoA-II, or treatment with 
an apoA-I peptide mimetic, or with normal HDL, or paraoxonase, also rendered the cells unable to oxidize 
LDL (50). 
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Human HDL can also directly reduce cholesteryl ester hydroperoxides and phosphatidylcholine 
hydroperoxides via Met residues 112 and 148 of apoA-I (51). Recombinant HDL containing only apoA-I 
and 1-palmitoyl-2-oleoyl-phosphatidylcholine (POPC) was as effective as native HDL in preventing LDL 
oxidation, supporting a key anti-oxidant role for apoA-I (52). In vivo studies have demonstrated that apoA-
I can act as an anti-oxidative, anti-inflammatory and anti-atherosclerotic agent (53-55). Recent clinical 
studies have suggested that although very high HDL–cholesterol and large-size HDL particles levels may 
be associated with an increased cardiovascular risk, a high concentration of apoA-I was an independent 
negative predictor of cardiovascular risk (56).  
Interestingly, several other HDL-associated apolipoproteins have also been shown to exert anti-oxidant 
effects.  ApoA-II-enriched HDL from mice transgenic for human apoA-II protected VLDL from oxidation 
more efficiently than control HDL (57). However, in other studies, overexpression of human apoA-II in 
dyslipidemic mice accelerated atherosclerosis and reduced anti-oxidative activity of HDL (58, 59). The 
authors postulated that the proatherogenic actions of apoA-II may be related to the displacement of apoA-
I and PON1 by apoA-II from HDL particles (58). Of note, in a nested case-control study in the prospective 
EPIC-Norfolk (European Prospective Investigation into Cancer and Nutrition-Norfolk) cohort, apoA-II was 
found to be associated with a decreased risk of future CAD in apparently healthy subjects (60).  
Apolipoprotein E has been shown to have allele-specific anti-oxidant activity (61). Apolipoprotein E2 can 
stimulate endothelial NO release and has anti-inflammatory activities (62). In contrast, apolipoprotein E4 
has been described as pro-inflammatory (63). It has also been reported that HDL-associated apolipoprotein 
J can inhibit LDL oxidation by artery wall cells (64). In addition, apoA-IV has been demonstrated to exert 
anti-oxidant, anti-inflammatory and anti-atherosclerotic actions in vivo (65-67). 
Notably, HDL carries also anti-oxidant enzymes that may be involved in prevention of lipid oxidation or 
degradation of lipid hydroperoxides, such as PON1, LCAT and platelet-activating factor acetylhydrolase 
(PAF-AH). In particular, PON1 has been suggested to be an important regulator of the potential anti-
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atherogenic capacity of HDL (68, 69). Various studies have suggested that the direct anti-oxidant effect of 
HDL on LDL oxidation, measured as a reduction in lipid peroxides, is to a significant extent mediated by 
PON1 (70-72). In human studies, higher PON1 activity is associated with a lower incidence of major 
cardiovascular events and conversely reduced activity of PON1 is associated with pathological conditions 
such as  chronic renal failure, rheumatoid arthritis and Alzheimer’s disease, as reviewed elsewhere (73).  
Biochemical studies have suggested the anti-oxidant role of LCAT through its capacity to hydrolyze 
oxidized acyl chains from phosphatidylcholine-based OxPL and oxidized free fatty acids (74, 75). In vivo 
study in mice deficient for LDL-receptor and leptin showed that LCAT overexpression decreased 
autoantibodies to oxLDL (76). PAF-AH is another HDL-associated enzyme that can hydrolyze oxidized 
phospholipids (77, 78). In arteries of non-hyperlipidaemic rabbits, local expression of PAF-AH reduced the 
accumulation of oxidatively modified LDL without changing plasma levels of PAF-AH and reduced the 
expression of endothelial cell adhesion molecules (79). In human studies, PAF-AH deficiency through a 
missense mutation of the gene is an independent risk factor for coronary artery disease in Japanese men 
(80). Circulating levels of PAF-AH is also shown to be an independent marker of the risk of CAD (81). 
However, in a recent study by Holleboom et al., reduced LCAT activity and PAF-AH activity due to LCAT 
mutations was not associated with increased plasma lipid peroxidation (82). 
HDL has also been shown to promote efflux of 7-ketocholesterol (83, 84) at sites of inflammation and 
thereby reduces endothelial cell inflammatory activation (85). Accordingly, Nicholls et al. have reported 
that reconstituted HDL inhibits superoxide production and vascular inflammation induced by a non-
occlusive carotid periarterial collar in normocholesterolemic rabbits (54). In addition, Van Linthout et al. 
have observed that human apoA-I gene transfer in rats with streptozotocin-induced diabetes mellitus 
resulted in a 1.9-fold increase in HDL cholesterol levels and inhibition of angiotensin II type 1 receptor-
mediated NAD(P)H oxidase activation and generation of reactive oxygen species (86).  
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Alterations of the effects of HDL from patients after surgery, with CAD or diabetes on LDL oxidation  
Early studies by van Lenten et al. have demonstrated that the anti-inflammatory capacity of HDL is affected 
by acute phase responses in both humans and rabbits (87). The authors isolated human HDL from the 
patients before and immediately after surgery and characterized the effects of HDL on LDL-induced 
monocyte transmigration and lipid hydroperoxide formation (87). Before cardiac surgery, HDL completely 
inhibited the LDL-induced increase in monocyte transmigration and lipid hydroperoxide formation. In 
marked contrast, “acute phase” HDL obtained from the same patients 2-3 days after surgery amplified the 
LDL-induced monocyte transmigration and was less effective in inhibiting lipid hydroperoxide formation, 
i.e. HDL in the same patient had been transformed from an anti-inflammatory towards a pro-inflammatory 
particle (87). Interestingly, the changes in HDL functionality in this study were paralleled by an increase in 
HDL-associated acute phase reactants (i.e. ceruloplasmin and serum amyloid A), while the activities of the 
HDL-associated anti-oxidant enzymes paraoxonase and platelet-factor activating acetylhydrolase were 
reduced in acute phase HDL (87). Similarly, an acute Influenza A infection in wild type mice progressively 
impaired the ability of HDL to inhibit LDL oxidation and LDL-induced monocyte chemotactic activity in 
human artery wall cell co-cultures up to 9 days after inoculation (88).  
HDL from patients with CAD failed to prevent LDL oxidation (50) and HDL from mice genetically 
predisposed to diet-induced atherosclerosis became proinflammatory when the mice were fed an 
atherogenic diet (89).  A subsequent study by Ansell et al. suggested that the capacity of HDL to alter LDL-
induced monocyte chemotactic activity in patients with CAD was somewhat improved after 6 weeks of 
simvastatin therapy (30). However, HDL from patients with CAD on statin therapy remained 
proinflammatory in contrast to HDL from age- and sex-matched healthy subjects.  
Navab et al. developed a fluorescent cell-free assay to detect the capacity of HDL to inhibit the oxidation 
of LDL, or inhibit the oxidation of l-α-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine 
(PAPC) by hydroperoxyoctadecadienoic acid (HPODE), or inactivate oxidized PAPC (Ox-PAPC) (90). 
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Using this assay, HDL isolated from 27 patients with coronary atherosclerosis failed to inhibit the 
fluorescent signal generated by a control LDL, whereas HDL from 31 matched normal subjects with the 
same levels of HDL cholesterol significantly inhibited the signal (90). 
The presence of oxidized lipids in HDL has been proposed to play a role in the altered anti-oxidant 
properties of HDL (91). Administration of apoA-1 mimetic peptides, L-4F, to apoE deficient mice has been 
shown to reduce plasma levels of oxidized fatty acids (15-HETE, 5-HETE, 13-HODE and 9-HODE ) and 
improve the HDL anti-oxidant capacity and the capacity of HDL to inhibit LDL-induced monocyte 
chemotactic activity in cultured human aortic endothelial cells (92). Moreover, in a recent study by 
Morgantini et al., HDL from patients with type 2 diabetes had impaired anti-oxidant properties and 
increased oxidized fatty acids content (93). The authors postulated that elevated content of oxidized fatty 
acids (5-HETE, 9-HETE, 12-HETE, 15-HETE, 9-HODE, and 13-HODE) in HDL isolated from the type 2 
diabetics patients may account for the impaired anti-oxidant properties of the lipoprotein (93). In another 
study, the ability of HDL to inhibit LDL oxidation was found to be reduced in ACS but not in stable CAD 
patients (94). Very recently, the same group also reported that the anti-oxidative and cholesterol efflux 
capacities of HDL are reduced in ischaemic cardiomyopathy (95).  
 
Effects of HDL on endothelial NO-Synthase dependent Nitric Oxide production: Experimental studies 
and altered effects of HDL from patients with cardiovascular disease   
Endothelial nitric oxide plays a crucial role in the regulation of vascular tone and structure. Endothelial NO 
synthase derived NO has been shown to exert a variety of athero-protective effects in the vasculature, such 
as anti-inflammatory  and anti-thrombotic  effects (96). Reduced endothelial NO bioavailability has 
therefore been suggested to promote initiation and progression of atherosclerosis (96).  
Accumulating evidence suggests that HDL can directly stimulate endothelial NO synthase mediated NO 
production via endothelial SR-BI (9).  Several experimental studies have consistently demonstrated the 
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capacity of HDL to modulate eNOS expression and to stimulate endothelial NO production in vitro and in 
vivo (10, 13, 15, 97-99). Moreover, in human studies, administration of reconstituted HDL has been shown 
to improve endothelial function in subjects with hypercholesterolemia and in subjects with isolated low 
HDL due to heterozygous loss-of-function mutations in the ABCA-1 gene locus (100, 101). It is worth 
noting that one can only speculate on how exactly the reconstituted HDL mixes with endogenous circulating 
HDL. 
Several mechanisms have been proposed to account for the endothelial NO-stimulating capacity of HDL. 
Early studies have shown that HDL prevents oxLDL-mediated eNOS displacements from caveolae and 
restores enzyme stimulation (102). A study by Yuhanna et al. suggested that HDL can bind to endothelial 
SR-BI and thus directly stimulate eNOS-mediated NO production (9). HDL binding to SR-BI initiates 
tyrosine kinase Src-mediated activation of phosphoinositide (PI) 3-kinase, which in turn activates Akt and 
the MAP kinase/extracellular signal-regulated kinase pathway (98). Activation of endothelial Akt by HDL 
stimulates phosphorylation of eNOS at serine residue 1177 (Figure 2) (10, 98), which is known to be an 
important regulatory mechanism leading to eNOS activation (103). 
Another mechanism has also been identified whereby HDL can maintain endothelial cell NO production 
and availability in mice fed a high-cholesterol diet (83). These authors suggested that HDL-induced 
ABCG1-mediated efflux of oxysterols from endothelial cells plays a role since 7-ketosterol, a dietary 
oxysterol, accumulated in endothelial cells of ABCG1- deficient mice on a western diet (83). Interestingly, 
incubation of human aortic endothelial cells with HDL prevented 7-ketosterol-induced production of 
reactive oxygen species and disruption of the active eNOS dimer. Furthermore, HDL-mediated cholesterol 
efflux via ABCG-1 reduced the inhibitory interaction of eNOS with caveolin-1 and thereby restored eNOS 
activity in cholesterol-loaded endothelial cells (104). These data suggest that the ability of HDL to preserve 
endothelial function in the presence of hypercholesterolemia may, at least in part, relate to an increased 
endothelial efflux of oxysterols. 
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Various components of HDL have been suggested to play a role in its endothelial NO-stimulating capacity. 
In cultured endothelial cells, the potential interaction of apoA-I with eNOS has been reported (99). 
However, despite being the ligand for SR-BI, a major HDL receptor, lipid-free apoA-I failed to activate 
eNOS, suggesting that other HDL components may be important or are required to support the 
conformation of apoA-1 to allow it to interact with SR-BI and to stimulate eNOS (105). In isolated endothe-
lial cell plasma membranes, anti-apoA-I antibody inhibits eNOS activation by HDL, whereas anti-apoA-II 
antibody further enhances eNOS stimulation by HDL (9). Several studies have suggested that HDL-
associated lysophospholipids may play a role in eNOS activation. Of note, HDL-associated 
sphingosylphosphorylcholine, sphingosine-1-phosphate, lysosulfatide may cause eNOS-dependent 
relaxation of precontracted aortic rings from mice via binding to the lysophospholipid receptor S1P3 
expressed on endothelial cells (10). The vasodilatory response to HDL, however, was not completely 
inhibited in S1P3 deficient mice (10).  
Recently, we observed that the HDL-associated antioxidant enzyme paraoxonase-1 (PON1) as an important 
determinant of the capacity of HDL to stimulate endothelial NO production and to exert NO-dependent 
endothelial- atheroprotective effects (15). Inhibition of PON1 in HDL from healthy subjects impaired the 
capacity of HDL to stimulate endothelial NO production and HDL isolated from PON1-deficient mice 
failed to stimulate NO production in mouse aortic endothelial cells (15). Furthermore, inhibition of eNOS-
mediated NO production prevented the inhibitory effects of HDL from healthy subjects on nuclear factor 
kB (NF-kB) activity, vascular cell adhesion molecule (VCAM)-1 expression and endothelial monocyte 
adhesion, suggesting that the capacity of HDL to stimulate endothelial NO production is important for these 
endothelial anti-inflammatory effects of HDL (15). 
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Alterations of the effects of HDL from patients with cardiovascular disease on endothelial NO 
availability  
We and others have recently shown that direct endothelial effects of HDL from patients with CAD or 
diabetes are markedly altered when compared to HDL from healthy subjects. In contrast to HDL from 
healthy subjects, HDL from patients with diabetes or chronic kidney disease failed to stimulate endothelial 
cell NO production and to promote endothelial repair in a carotid artery injury model in mice (13, 106).  
Moreover, HDL from patients with either stable CAD or an acute coronary syndrome, in contrast to HDL 
from age- and gender-matched healthy subjects, inhibited rather than stimulated endothelial cell NO 
production and lost the capacity to limit endothelial inflammatory activation as well as to promote 
endothelial repair in vivo (15). 
Notably, we have observed that malondialdehyde (MDA) content is elevated in HDL from patients with 
coronary disease as compared to HDL from healthy subjects, which may limit endothelial NO production 
(15) (Figure 2). The antagonistic action of MDA was determined to be mediated by lectin-type oxidized 
LDL receptor 1 activation of protein kinase C-βII, which inhibits Akt-activating phosphorylation at Ser473 
and eNOS-activating phosphorylation at Ser1177 (Figure 2). Because MDA formation is decreased by 
HDL-associated PON1 (107), PON1 activity was evaluated and was found to be markedly decreased in 
HDL from patients with coronary disease (15). Furthermore, PON1 inactivation in HDL from healthy 
subjects results in greater protein kinase C-βII activation in cultured endothelial cells, decreased activating 
eNOS-Ser1177 phosphorylation, and increased inactivating eNOS-Thr495 phosphorylation, resulting in 
attenuated NO production. Furthermore, HDL from PON1-deficient mice failed to stimulate endothelial 
cell NO production (15). These observations suggest that alterations of HDL-associated PON1 may have a 
major impact on endothelial effects of HDL.  
An inverse relationship between PON1 serum activity and cardiovascular events has been reported (108, 
109). A recent analysis of SNPs for PON1 identified in genome wide association studies did not reveal a 
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significant association between the lead SNPs for PON1, that was associated with mildly reduced 
paraoxonase activity, and the risk of cardiovascular events (110).  A difficulty with respect to PON1 is that 
it is not known to what extent the paraoxonase and arylesterase activities of the enzyme represent 
biologically relevant functions.  We and others have observed important post-translational modifications of 
the enzyme, which could lead to further alterations of biological properties of the enzyme (15, 111). 
 
Effects of HDL on endothelial cell inflammatory activation: Experimental studies and alterations of 
the effects of HDL from patients with cardiovascular disease 
Atherosclerosis is a chronic inflammatory disease.  Endothelial adhesion and subsequent infiltration and 
accumulation of monocytes/macrophages and T lymphocytes into the arterial intima represent critical steps 
in initiation and progression of atherosclerotic lesions (46). HDL has been shown to inhibit the expression 
of monocyte chemoattractant protein (MCP)-1, an important pro-inflammatory chemokine in endothelial 
cells (91, 112). Studies have demonstrated that native HDL and reconstituted HDL containing apoA-I or 
the apoA-I Milano mutant inhibit the expression of leukocyte adhesion molecules in endothelial cells that 
are activated by pro-inflammatory stimuli (113, 114). Furthermore, HDL has been suggested to inhibit 
endothelial monocyte adhesion induced by oxLDL (115) or TNF-α (116) and monocyte transmigration in 
co-cultures of human aortic endothelial cells and smooth muscle cells stimulated with LDL (91).  
The potential anti-inflammatory effects of HDL have also been demonstrated by several in vivo studies. 
Administration of reconstituted human HDL in apoE-deficient mice reduced VCAM-1 expression and 
decreased monocyte/macrophage infiltration following carotid artery cuff injury (117). Recently, it was 
shown that apoA-I gene transfer resulting in increased HDL cholesterol plasma levels inhibited diabetes-
induced myocardial mRNA expression of VCAM-1 and ICAM-1 in mice with streptozotocin-induced 
diabetic cardiomyopathy (118). In contrast, in a study in apoE-deficient mice with transgenic 
overexpression of human apoA-I, endothelial VCAM-1 expression monocyte adherence were not reduced 
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in early atherosclerotic lesions at the aortic branch sites, despite reducing aortic atherosclerotic lesion 
formation (119).  Hence, these observations support the concept that the anti-inflammatory capacity of HDL 
is heterogeneous, depending on the pathophysiological conditions, that is also consistent with findings of 
recent studies demonstrating that the inhibitory effects of HDL isolated from different human subjects on 
TNF-α stimulated endothelial VCAM-1 expression varied considerably (87, 120). In human studies, it has 
been suggested that administration of reconstituted HDL increased the anti-inflammatory capacity of HDL 
from patients with type-2 diabetes (121). 
Several mechanisms have been suggested to explain the inhibitory effects of HDL on endothelial 
inflammatory activation (8). HDL can inhibit activation of the endothelial pro-inflammatory transcription 
factor NF-κB (116, 122). Impaired endothelial NO bioavailability and increased endothelial superoxide 
production have been implicated in activation of NF-κB (123). Furthermore, it was demonstrated that 
endothelial anti-inflammatory effects of HDL are mediated via SR-BI, PDZK1, PI3 kinase, eNOS, and S1P 
receptors (124). Recently, we have observed that inhibition of eNOS-mediated NO production reduced the 
inhibitory effects of HDL from healthy subjects on nuclear  factor kB (NF-kB) activity, VCAM-1 
expression and endothelial monocyte adhesion, suggesting that the capacity of HDL to stimulate endothelial 
NO production contributes to these endothelial anti-inflammatory effects of HDL (15).  
It has been proposed that apoA-1, the major protein constituent of HDL, is able to recapitulate the anti-
inflammatory capacity of HDL. In an in vivo study, infusion of apoA-I to rabbits subjected to acute vascular 
inflammation reduced neutrophil infiltration and endothelial cell inflammatory activation (125). 
Furthermore, administration of apoA-1 mimetic peptides, D-4F and L-4F has been shown to reduce vascular 
inflammation in type I diabetic rats and improved insulin sensitivity in obese mice (126, 127). Furthermore, 
lipid-free apoA-I and rHDL treatment reduced the expression of chemokines and chemokines receptors in 
vivo and in vitro via modulation of NF-κB and peroxisome proliferator–activated receptor γ (128). One of 
the potential mechanisms for the anti-inflammatory effect of apoA-I is by mediating cellular cholesterol 
efflux through ABCA1, an ATP-binding transporter (129, 130). Interestingly, apoA-I has also been shown 
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to attenuate palmitate-induced NF-kB activation by reducing toll-like receptor-4 recruitment into lipid rafts 
(131).  
Besides apoA-I, the lipid component of HDL has also been proposed to be important for the anti-
inflammatory effects of HDL. In vitro studies using discoidal reconstituted HDL containing apoA-I as the 
sole protein suggested that inhibitory effects of HDL on endothelial cell adhesion molecule expression are 
also, at least in part, dependent on HDL-associated phospholipid species (132). The inhibition of cytokine 
induced expression of VCAM-1 by reconstituted HDL varied substantially when different 
phosphatidylcholine species were compared, indicating that the lipid composition of HDL influences its 
anti-inflammatory capacity and might be an important determinant of HDL functionality (8, 132). 
Alterations of effects of HDL from patients with coronary disease, diabetes or chronic kidney dysfunction  
on endothelial inflammatory activation 
Early studies have demonstrated that the anti-inflammatory capacity of HDL is lost during acute phase 
responses in both humans and rabbits, as shown by the impaired ability of the isolated HDL to protect LDL 
from oxidation and inhibit the adhesion of monocytes to endothelial cells  (87, 88). Furthermore, the 
capacity of HDL to inhibit LDL-induced monocyte chemotactic activity has also been shown to be impaired 
in CAD patients (89), which can be improved following simvastatin therapy (30). Recent studies have also 
described that the HDL capacity to inhibit the expression of adhesion molecules and monocyte chemotactic 
activity is lost in patients with CAD, diabetes, as well as end-stage renal disease (15, 93, 133). 
Various mechanisms have been proposed to account for the impaired endothelial anti-inflammatory effects 
of HDL. The decrease in HDL apoA-I levels in inflammatory states has been related to decreased apoA-I 
synthesis in the liver, accelerated HDL catabolism, and apoA-I replacement in HDL particles by serum 
amyloid A (SAA) (134, 135). Upon induction of the acute phase, SAA is able to replace apoA-I in small, 
dense HDL, resulting in reduced plasma levels of apoA-I (136). In rabbits and mice, SAA can completely 
replace apoA-I in a subset of small, dense HDL particles, therefore functioning as a structural 
16 
 
apolipoprotein (137). Accordingly, SAA was recently found to be enriched in HDL from ESRD patients, 
which correlated with its reduced anti-inflammatory capacity to inhibit monocyte chemoattractant protein-
1 formation in vascular smooth muscle cells (133). 
In addition, certain amino acid residues in apoA-I, such as methionine, cysteine, tyrosine, and lysine 
residues are susceptible to oxidative modifications (138, 139). In vitro study has demonstrated that MPO-
catalysed oxidative modification of HDL or apoA-I converts HDL into a pro-inflammatory particle which 
promotes NF-κB activation and endothelial VCAM-1 expression (140). Furthermore, glycation of HDL 
and apoA-I, a process that is known to occur in diabetes in vivo (141), has also been proposed to impact on 
the anti-inflammatory capacity of HDL (142). In contrast to normal lipid-free ApoA-I, glycated lipid-free 
apoA-I infusion did not decrease adhesion molecule expression following vascular injury (142). Glycation 
of HDL has also been shown to impair the HDL capacity to inhibit oxLDL-induced monocyte adhesion to 
human aortic endothelial cells in vitro (143). 
 
Effects of HDL on endothelial cell apoptotic pathways: Experimental studies and alterations of effects 
of HDL from patients with coronary disease 
Endothelial dysfunction and injury contribute to the pathogenesis of atherosclerosis (96, 144, 145).  
Experimental studies have shown that atherosclerotic lesion-prone vascular regions are characterized by a 
high endothelial cell turn-over (146), which has been attributed to an increased rate of endothelial cell 
apoptosis. Endothelial cell apoptosis has also been suggested to contribute importantly to the 
pathophysiology of coronary disease (147, 148). The capacity of HDL to attenuate endothelial cell 
apoptosis may therefore represent an anti-atherogenic property of HDL (149-152). 
HDL inhibits apoptosis of endothelial cells induced by both death-receptor-mediated and mitochondrial 
mediated apoptotic pathways. HDL may inhibit apoptosis triggered by various proatherogenic factors, such 
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as TNF-α, oxLDL and growth factor deprivation (149-151). Both HDL-associated proteins and lipids have 
been suggested to contribute to the anti-apoptotic capacity of HDL. ApoA-I has been shown to inhibit 
endothelial cell apoptosis induced by oxLDL, VLDL, and TNF-α (150, 151, 153). HDL subpopulations 
enriched with apoA-I account for approximately 70% of the anti-apoptotic activity of HDL in human 
microvascular endothelial cells that were treated with mildly oxLDL and reconstitution of HDL with apoA-
I, cholesterol and phospholipids potently decreased oxLDL-induced apoptosis in these cells (152), 
suggesting that apoA-I plays an important role for the anti-apoptotic capacity of HDL in oxLDL-stimulated 
endothelial cells. 
HDL-associated lysosphingolipids have also been shown to inhibit endothelial cell apoptosis triggered by 
growth factor deprivation (149, 154, 155). The anti-apoptotic capacity of HDL-associated lipids was further 
supported by the findings that the ratio of sphingosine-1-phosphate and sphingomyelin was increased in 
small dense HDL3 particles and positively correlated with the capacity of these HDL subpopulations to 
attenuate endothelial cell apoptosis (156).  
Several mechanisms have been proposed for the endothelial anti-apoptotic effects of HDL, depending on 
the trigger of apoptosis. OxLDL causes a delayed but sustained increase in intracellular calcium in 
endothelial cells, leading to cell death, and this effect is reversed by HDL and mediated by prevention of 
the calcium increase (151). Tumor necrosis factor-α–induced endothelial cell apoptosis is also inhibited by 
HDL, and this is associated with attenuated induction of CPP32-like protease (caspase 3), which is a 
component of all primary apoptotic pathways (150). Growth factor deprivation activates the mitochondrial 
pathway of apoptosis, which can be suppressed by HDL. HDL inhibits the dissipation of mitochondrial 
potential, oxygen-derived free radical generation, cytochrome c release to the cytoplasm, and activation of 
caspase 3 and caspase 9. HDL also activates Akt and causes phosphorylation of the Akt target Bcl-2-
associated death promoter Bad, preventing it from binding to Bcl-xL (Figure 2). Bcl-xL, an anti-apoptotic 
Bcl-2 family protein, is then free to inhibit mitochondria-mediated apoptosis (149). In addition, HDL causes 
phosphoinositide 3 (PI3) kinase mediated up-regulation of the Bcl-xL expression (16). Interestingly, HDL 
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retained its anti-apoptotic activity after knockdown of eNOS using specific RNA interference or 
pharmacological inhibition using L-NAME (16), suggesting that HDL may exert its anti-apoptotic activity 
independently of eNOS activation. The lysophospholipid sphingosine-1-phosphate (S1P) enhances 
endothelial cell survival, and these effects are inhibited by knockdown of the S1P receptor endothelial 
differentiation gene-1/S1P1 by pertussis toxin and by phosphoinositide 3 (PI3) kinase and Erk pathway 
antagonists, suggesting that signaling by lysophospholipid components of HDL may be important for the 
inhibition of apoptosis (155).  
Alterations of the effects of HDL from patients with cardiovascular disease on endothelial apoptosis 
Recently, we have observed that reduced clusterin and increased apolipoprotein C-III content in HDL 
isolated from patients with CAD lead to activation of pro-apoptotic signaling pathways in endothelial cells 
(16). In contrast to HDL from healthy subjects, HDL isolated from patients with stable CAD or an acute 
coronary syndrome failed to inhibit endothelial cell apoptosis in vitro and in apoE-deficient-mice in vivo. 
Instead, HDL isolated from these patients stimulated endothelial pro-apoptotic pathways, in particular p38-
MAPK-mediated activation of the pro-apoptotic Bcl-2-protein tBid (Figure 2). Our studies further suggest 
that differences in the proteome of HDL from patients with CAD, in particular reduced HDL-associated 
clusterin and increased HDL-associated apoC-III, play an important role for altered activation of endothelial 
anti- and pro-apoptotic signaling pathways (Figure 2) (16). Furthermore, oxidative modifications of HDL 
may also play a role in the loss of anti-apoptotic activity of HDL, as demonstrated by Undurti et al. showing 
that MPO-catalyzed oxidation of HDL resulted in the impaired capacity to inhibit endothelial apoptosis in 
vitro (140).   
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Effects of HDL on endothelial repair after vascular injury: Experimental studies and effects of HDL 
from patients with cardiovascular disease 
Recent studies have also suggested that HDL may stimulate endothelial repair processes. Endothelial repair 
processes have long been thought of to be only dependent on the proliferation and migration of local 
adjacent endothelial cells (146), however several recent studies have demonstrated that bone-marrow 
derived mononuclear cells (early outgrowth cells; EOCs) can promote endothelial repair after vascular 
injury (157, 158),  and likely contribute to endothelial repair processes in lesion-prone areas of experimental 
atherosclerosis and improve endothelial function (159, 160).  
HDL stimulates endothelial repair by promotion of endothelial cell proliferation or migration and 
stimulation of the recruitment and endothelial repair capacity of EOCs (13, 161, 162). HDL induces a 
marked increase in endothelial cell migration in vitro with effects comparable to endothelial growth factors, 
such as basic fibroblast growth factor or vascular endothelial growth factor (155, 161, 163). Native HDL 
and the HDL-associated lysosphingolipid sphingosine-1-phosphate stimulate endothelial cell migration via 
sphingosine-1-phosphate receptors S1P1 and S1P3 and the effects could be blocked by pertussis toxin 
which inhibits the interactions between G proteins and G protein-coupled receptors (155). The importance 
of sphingosine-1-phosphate for endothelial cell migration was supported by another study demonstrating 
that sphingosine-1-phosphate induced tube formation of human coronary artery endothelial cells in vitro by 
Ras/Raf1-dependent ERK activation (164). In contrast, in a work by Seetharam et al. pertussis toxin did not 
affect HDL-mediated endothelial cell migration (161), suggesting the presence of another pathway and 
agonist, which induces the migration of endothelial cells by HDL. Indeed, the authors observed that 
reconstituted HDL consisting of apoA-I, palmitoyloleylphosphatidylcholine and cholesterol was able to 
induce endothelial cell migration (161). Moreover, native HDL induced rapid changes in the actin 
cytoskeleton of endothelial cells (i.e. a decrease in stress fibers, an increase in lamellipodia, and membrane 
ruffling) paralleled by an activation of the small GTPase Rac, that is known to mediate lamellipodia 
formation (161). Interestingly, the authors were able to demonstrate that endothelial Rac activation and 
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migration in response to HDL is independent of endothelial NO production, but requires binding of HDL 
to SR-BI and activation of Src kinase, PI3-kinase and MAP kinase (161). PDZ domain-containing protein 
PDZK1 was identified as an adaptor protein of SR-BI in endothelial cells and it was suggested that PDZK1 
is required for the initiation of HDL signalling via SR-BI in endothelial cells and plays an important role 
for endothelial cell migration induced by HDL (162). Interestingly, further studies have suggested that HDL 
and SR-BI promote re-endothelialization of the carotid artery after perivascular electric injury in mice (13, 
161). In this model, carotid artery re-endothelialization was impaired in apoA-I deficient mice with low 
HDL levels as well as in SR-BI deficient mice. Of note, reconstitution of apoA-I expression by liver-
directed apoA-I gene transfer with subsequent normalisation of HDL plasma levels restored the re-
endothelialization response in apoA-I deficient mice, strongly suggesting that apoA-I and HDL promote 
endothelial monolayer integrity in vivo (161). In another study, elevation of HDL levels in apoE-deficient 
mice induced by adenoviral human apoA-I (AdA-I) transfer increased the number of Flk1 / Sca-1 double-
positive cells in peripheral blood and the number of DiIacLDL / FITC-isolectin double positive cells after 
4 days of ex vivo culture of spleen mononuclear cells (165).  
Besides increasing the number of EOCs, AdA-I transfer in apoE-deficient mice improved the migratory 
capacity of spleen-derived early EOCs in response to HDL, the adhesion of spleen-derived early EOCs to 
fibronectin and the invasion of spleen-derived early EOCs in solidified Matrigel (165). Finally, AdA-I 
transfer also promoted the incorporation of EOCs in Balb/c common carotid artery allografts transplanted 
paratopically in C57BL/6 ApoE-/- mice that was associated with an increase in endothelial regeneration 
and inhibition of transplant arteriosclerosis (165). In a follow-up study, the same group observed that 
murine and human early EOC express SR-BI, as indicated by immunocytochemistry analysis of human 
early EOCs and murine spleen-derived early EOCs after 4 and 7 days of ex vivo culture (166). Of note, the 
authors did not observe an increase in circulating Flk1 / Sca-1 double-positive cells and DiI-acLDL / FITC-
isolectin double positive cells after ex vivo culture of spleen mononuclear cells after AdA-I transfer in mice 
transplanted with SR-BI deficient bone marrow, suggesting that expression of SR-BI in bone marrow is 
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critical for EOC mobilisation induced by HDL (166). Furthermore, the migratory capacity of bone-marrow 
derived early EOC deficient in SR-BI in response to HDL was reduced as compared to early EOCs 
containing SR-BI and this was at least in part due to an impaired activation of extracellular signal-regulated 
kinases (ERK) and decreased NO production in SR-BI deficient early EOCs (166). In vivo, SR-BI 
deficiency in bone marrow abrogated the inhibitory effect of AdA-I transfer on allograft vasculopathy after 
paratopical transplantation of a common carotid artery of a female BALB/c donor mouse into the recipient 
male C57BL/6 mice, that was paralleled by impaired endothelial regeneration and EOC incorporation in 
allografts (166). Besides increasing HDL levels by adenoviral human apoA-I transfer, intravenous infusion 
of reconstituted HDL has also been shown to increase the number of Sca-1 positive cells in the aortic 
endothelium of apoE deficient mice, supporting a role for HDL in promoting endothelial repair (167). 
Furthermore, intravenous injection of reconstituted HDL increased blood flow recovery and capillary 
density in a murine ischemic hindlimb model (168).  
Of note, a pivotal role for eNOS in the regulation of EOC mobilization was shown using eNOS-deficient 
mice, which demonstrated an impaired capacity to mobilize EOCs and impaired function of isolated EOCs 
(169). Studies have demonstrated that colony-forming capacity and migratory function of circulating EOCs 
are impaired in conditions associated with reduced NO bioavailability, suggesting a link between eNOS 
activity and EOC function (170, 171). The effects of HDL on circulating EOCs may also involve increasing 
cell survival and prevention of apoptosis. HDL prevents apoptosis of early EOCs through inhibition of 
caspase-3 activity (172). Furthermore, administration of D-4F has been shown to cause EOCs to produce a 
robust increase in eNOS and heme oxygenase-1 thereby enhancing its survival which may contribute to 
vascular repair in diabetic rats (126). 
Alterations of the effects of HDL from patients with diabetes or CAD on endothelial repair processes  
Reconstituted HDL has been described to improve EOC availability in patients with type 2 diabetes, which 
have a reduced availability and impaired function of EOCs (173).  HDL from patients with type 2 diabetes 
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has recently been found to have a diminished capacity to stimulate endothelial cell proliferation, migration 
and adhesion to extracellular matrix and this impairment is associated with down regulation of SR-BI 
expression (174). Notably, we have observed that HDL from patients with CAD has impaired endothelial 
repair capacity following vascular injury in vivo using nude mice carotid artery injury model (15).    
 
Effects of HDL on endothelial thrombotic activation: Experimental studies and alterations of the 
effects of HDL from patients with diabetes 
There has been some direct evidence demonstrating potential anti-thrombotic actions of HDL.  In a rat 
model of acute arterial thrombosis, infusion of apoA-I Milano caused a prolongation in the time of thrombus 
formation and a reduction in the weight of the thrombus (175).  In humans, infusion of reconstituted HDL 
limited development of a procoagulant state in healthy volunteers given low doses of endotoxin (176). One 
potential mechanism contributing to anti-thrombotic effects of HDL is an increased endothelial prostacyclin 
synthesis.  Prostacyclin acts synergistically with NO to induce vascular smooth muscle relaxation, inhibits 
platelet activation, and diminishes the release of growth factors that stimulate the local proliferation of 
smooth muscle cells (177). Incubation with native HDL increases prostacyclin production in cultured 
endothelial cells (178, 179), and the effects can be recapitulated partially by delipidated HDL (180), 
suggesting that both HDL-associated lipids and  apolipoproteins are involved in the process. Prostacyclin 
release has also been shown to increase when isolated rabbit and rat hearts are infused with HDL (181, 
182). The impact of HDL on prostacyclin production in endothelium occurs by both the provision of 
arachidonate (178, 180, 183) and upregulation of Cox-2 expression (184, 185). It has also been observed 
that HDL3 induces Cox-2 expression and prostacyclin release via a p38 MAP kinase/CREB-dependent 
pathway in the endothelium (185-188). Recently, it was demonstrated that apoA-I, but not apoA-II, induced 
the expression of Cox-2 and the production of prostacyclin through the p38 MAPK, ERK1/2 and JAK2 
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pathways via ABCA1 in endothelial cells (189). Involvement of SR-BI mediated PI3K-Akt-eNOS signaling 
in HDL-induced Cox-2 expression and prostacyclin release in endothelial cells has also been reported (190). 
Increased tissue factor and selectin expression on platelets and endothelial cells have been identified as 
critical factors in the initiation of thrombus formation. The phospholipid components of HDL have been 
demonstrated to contribute to the downregulation of E-selectin expression on endothelial cell surfaces (8, 
184).  Furthermore, reconstituted HDL has been shown to downregulate thrombin-induced endothelial cell 
tissue factor expression in vitro (191). HDL has also been shown to exert antithrombotic effects by 
inhibiting platelet activation. The administration of reconstituted HDL to humans or the infusion of apoA-
I Milano into rats inhibits platelet aggregation (176, 192). HDL may regulate platelet function by down-
regulating the release of platelet activating factor or by upregulating endothelial NO synthesis and release 
(185, 193). HDL also downregulates the biosynthesis of thromboxaneA2 (TxA2) and upregulates 
prostacyclin production which can decrease platelet aggregation as well as blunt leukocyte-endothelial cell 
interactions and thereby prevent the initiation and progression of atherogenesis (194).  
Alterations of the effects of HDL from patients with diabetes on endothelial thrombotic activation  
While there is no direct evidence showing that the anti-thrombotic actions of HDL may be impaired in 
inflammatory conditions, the involvement of PI3K-Akt-eNOS pathways (190) and also p38 MAPK, 
ERK1/2 and JAK2 pathways (185, 189) in HDL-induced Cox-2 expression and prostacyclin release 
suggests that disruption in these pathways may likely leads to altered actions of HDL on endothelial cells 
relevant to thrombosis.  
However, interestingly, a study showed that oxidized HDL strongly inhibits platelet activation and 
aggregation (195). This anti-thrombotic action of oxidized HDL is mediated by SR-BI but independently 
of eNOS/Akt pathway (195). More recently, HDL from patients with early stages of type 2 diabetes has 
been reported to upregulate Cox-2 expression and prostacyclin release in endothelial cells, mediated via 
S1P receptors (196). The authors suggest that the increased in HDL-associated S1P levels in the early stage 
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of type 2 diabetes may contribute to the anti-thrombotic actions of HDL indicating a compensatory 
protective mechanism during the early course of the disease (196). More studies will be needed in this area 
to better understand the interaction between HDL and thrombotic pathways. 
 
Conclusion and Perspectives 
Over the past two decades numerous studies have revealed several direct effects of HDL on endothelial cell 
functions, including potentially anti-atherogenic properties.  It has become clear, that HDL particles are 
highly heterogenous and the vasoprotective effects of HDL are altered in patients with coronary disease, 
diabetes and chronic kidney dysfunction, i.e. patients with a high cardiovascular risk profile.  Most of the 
studies examining functions of HDL from healthy subjects or patients with cardiovascular disease have 
been performed ex vivo i.e. by using isolated HDL from different study populations and testing it in in vitro 
bioassays.  While these studies provide clear evidence for the heterogeneity of HDL particles and its altered 
effects on vascular cells, when HDL is obtained from patients with cardiovascular disease as compared to 
healthy subjects, the in vivo relevance of these functional alterations of HDL and the potential role for 
progression of coronary disease remains to be determined.  Notably, however, these findings have more 
recently been paralleled by observations in cohort studies, suggesting that in patients with advanced 
coronary disease, higher plasma levels of HDL cholesterol are no longer associated with a reduced risk of 
cardiovascular events (23, 197). 
Of note, the functional heterogeneity of HDL may be attributed to the complexity of the HDL particles, 
containing more than 50 proteins and numerous lipids that can be modified or altered in their composition.  
Recent advances in the field of HDL proteomics and lipidomics have been reviewed by Shah et al. (198) 
and Kontush et al. (199), respectively, in the same thematic review series by the Journal of Lipid Research.  
We are just beginning to understand which HDL subspecies may be responsible for specific vasoprotective 
properties of HDL. It is noteworthy that rapid advances in the MS proteome technology have allowed 
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tremendous leaps in characterizing the HDL proteome. Studies investigating the lipidome of HDL are still 
somewhat limited by the available technologies.  
Taken together, plasma HDL cholesterol levels are likely not an appropriate marker of vascular effects of 
high-density lipoproteins, and therefore itself do not represent a reliable therapeutic target.  HDL-targeted 
treatment approaches likely need to take into account the altered vascular effects of HDL in cardiovascular 
disease.  Moreover, targeting HDL-mediated anti-atherogenic mechanisms, rather than HDL cholesterol 
plasma levels, may represent a promising and interesting therapeutic target.  Further studies into the specific 
mechanisms leading to a loss of anti-atherogenic effects of HDL are in particular warranted, in order to in 
determine which therapeutic approaches may be particularly potent in restoring HDL’s vasoprotective 
properties.  The effect of such therapeutic approaches on HDL function will have to be tested in future 
studies.    
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Figure Legends 
 
Figure 1. Left panel – HDL from healthy subjects exerts direct vasoprotective effects, such as endothelial 
anti-inflammatory, anti-oxidative, anti-apoptotic and anti-thrombotic effects. HDL from healthy subjects 
stimulates endothelial cell nitric oxide production and promotes endothelial repair after vascular injury. 
Right panel - Accumulating evidence suggests that the vascular effects of HDL can be highly 
heterogeneous.  HDL loses potential anti-atherosclerotic properties in patients with chronic inflammatory 
diseases, such as coronary artery disease, that has been termed “HDL dysfunction”. Of note, HDL may also 
become a proinflammatory particle in certain pathophysiological conditions.    
 
Figure 2. Signaling pathways mediating the effects of HDL on endothelial NO production and endothelial 
apoptosis. HDL from healthy subjects binds to SR-BI via apoA-I, leading to PDZK1-dependent activation 
of Src family kinases, PI3K and Akt, which phosphorylates eNOS at serine residue 1177, therefore 
increasing eNOS activity. PI3K-dependent MAPK activation and binding of HDL-associated 
lysophospholipids to the S1P3 receptor also activate eNOS. In contrast, HDL from patients with CAD can 
suppress eNOS activation. Inactivation of PON1 and greater accumulation of MDA in HDL lead to LOX-
1-mediated activation of PKCβII and inhibition of eNOS by phosphorylation at threonine 495. HDL-
associated clusterin promotes endothelial anti-apoptotic signaling via activation of PI3K and Akt leading 
to increased expression of anti-apoptotic Bcl-xL. Akt activation also phosphorylates Bcl-2-associated death 
promoter Bad, preventing it from binding to Bcl-xL, which is then free to inhibit mitochondria-mediated 
apoptosis. In CAD, the level of HDL-associated clusterin is reduced, whereas HDL-associated apoC-III 
content is increased. HDL-associated apoC-III activates MAPK signaling via phosphorylation of p38 
leading to increased activation of pro-apoptotic tBid, which promotes cytochrome C release from the 
mitochondria and downstream caspase-3 mediated apoptosis.   
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Table 1. Summary of the endothelial vasoprotective effects of High-density lipoprotein and its alterations in pathophysiological states 
    
Endothelial function Mechanisms of effects of HDL Key components Alterations in Pathophysiological Settings 
Endothelial Protection  
by limiting LDL oxidation 
 
HDL prevents oxidation of LDL in vitro [41-43] 
 
ApoA-I, ApoE, ApoJ, 
PON1, LCAT, PAF-AH 
 
Impaired antioxidant capacity of HDL in patients with CAD 
[89, 90, 94] and ischaemic cardiomyopathy [95] 
 
 
HDL is a major carrier of lipid peroxidation products [44,45] 
 
Loss of antioxidant capacity of HDL after surgery in humans 
and rabbits [87] and after acute influenza in mice [88] 
 
Stimulation of  
Endothelial NO 
production 
Direct stimulation of eNOS via SR-BI and S1P3 [9,10,13,15,97-
99] 
ApoA-I, sphingosine-1-
phosphate, PON1 
Impaired capacity of HDL to simulate endothelial NO 
production in patients with CAD [15], diabetes [13], 
CKD[106],  antiphospholipid syndrome [25] 
 
Reduce inhibitory interaction of eNOS with caveolin-1 via 
ABCG1-mediated oxysterol efflux [83,104] 
 
Prevention of  oxLDL-mediated eNOS displacement from 
caveolae [102] 
  
 
Impact on Endothelial 
Inflammatory Activation 
 
Inhibition of endothelial monocyte adhesion in vitro [91,112-
116] 
 
Inhibition of endothelial VCAM-1 and ICAM-1 expression in 
vitro and in vivo [117-121] 
 
ApoA-I, 
phosphotidylcholine 
 
Impaired anti-inflammatory capacity of HDL in patients with 
CAD [15], diabetes [93] and ESRD [133] 
 
Displacement of apoA-I by SAA in rabbits and mice [134-137] 
   
Impaired anti-inflammatory capacity of apoA-I after MPO-
mediated oxidation in vitro [140], and of HDL after glycation 
in vitro [142,143] 
Impact of Endothelial  
Apoptotic Pathways 
Inhibition of endothelial apoptosis mediated by TNF-α, oxLDL, 
growth factor deprivation in vitro [149-151] 
 
ApoA-I, 
lysosphingolipids, 
clusterin 
Impaired anti-apoptotic capacity of HDL in patients with CAD 
with reduced clusterin and increased apoC-III content [16] 
  
Reduced anti-apoptotic capacity of HDL after MPO-catalyzed 
oxidation in vitro [140] 
 
Impact on Endothelial 
Repair after vascular 
injury 
Stimulation of  endothelial cell proliferation, migration and 
recruitment of early EOC in vitro and in vivo [13,161,162] 
 
ApoA-I, sphingosine-1-
phosphate 
 
Impaired HDL capacity to stimulate endothelial repair after 
vascular injury in patients with type 2 diabetes [173,174] and 
CAD [15] 
 Prevention of apoptosis of circulating EOCs [172]  
 
Impact on Endothelial 
Thrombotic Activation 
 
Increased prostacyclin synthesis in vitro [178,179] and in vivo 
[181,182] 
ApoA-I, phospholipids 
 
Oxidized HDL strongly inhibits platelet activation and 
aggregation [195] 
 
Stimulation of Cox-2 expression [185-188] and inhibition of E-
selectin expression [8,184] 
 
HDL isolated from patients with type 2 diabetes upregulates 
Cox-2 expression and prostacyclin release [196] 
 
Downregulation of endothelial cell tissue factor expression in 
vitro [191] 
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